Valbenazine

Drug Profile

Valbenazine

Alternative Names: INGREZZA; MT 5199; NBI-98854; VMAT2 inhibitor - Neurocrine Biosciences

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Huntington's disease; Schizophrenia

Most Recent Events

  • 21 Apr 2017 Launched for Drug-induced dyskinesia in USA (PO)
  • 20 Apr 2017 Discontinued - Preclinical for Schizophrenia in USA (PO)
  • 17 Apr 2017 Discontinued - Phase-I for Huntington's disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top